BiotechTube

teriparatide + raloxifene HCl + placebo

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Osteoporosis, Postmenopausal

Conditions

Osteoporosis, Postmenopausal

Trial Timeline

Oct 1, 2001 → Jul 1, 2005

NCT ID
NCT00035256

About teriparatide + raloxifene HCl + placebo

teriparatide + raloxifene HCl + placebo is a approved stage product being developed by Eli Lilly for Osteoporosis, Postmenopausal. The current trial status is completed. This product is registered under clinical trial identifier NCT00035256. Target conditions include Osteoporosis, Postmenopausal.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00035256ApprovedCompleted

Competing Products

20 competing products in Osteoporosis, Postmenopausal

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
77
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
77
TeriparatideEli LillyPhase 3
77
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
77
raloxifene + PlaceboEli LillyApproved
85
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
raloxifene + placeboEli LillyApproved
85
Teriparatide + Salmon CalcitoninEli LillyPhase 3
77
ForteoEli LillyPre-clinical
23
arzoxifene + PlaceboEli LillyPhase 2
52
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
77
CT-P41 + US-licensed ProliaCelltrionPhase 3
77
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
77
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
23
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
77
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
77
YM529 / ONO-5920Astellas PharmaPhase 2/3
65
ONO-5920Astellas PharmaPhase 3
77
Minodronic acid hydrateAstellas PharmaPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85